Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland - PubMed (original) (raw)
doi: 10.1038/sj.ejhg.5200529.
P Huusko, H Eerola, V Launonen, P Vehmanen, K Rapakko, E Gillanders, K Syrjäkoski, T Kainu, P Vahteristo, R Krahe, K Pääkkönen, J Hartikainen, C Blomqvist, T Löppönen, K Holli, M Ryynänen, R Bützow, A Borg, B Wasteson Arver, E Holmberg, A Mannermaa, J Kere, O P Kallioniemi, R Winqvist, H Nevanlinna
Affiliations
- PMID: 11039575
- DOI: 10.1038/sj.ejhg.5200529
Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland
L Sarantaus et al. Eur J Hum Genet. 2000 Oct.
Abstract
In the Finnish breast and ovarian cancer families six BRCA1 and five BRCA2 mutations have been found recurrently. Some of these recurrent mutations have also been seen elsewhere in the world, while others are exclusively of Finnish origin. A haplotype analysis of 26 Finnish families carrying a BRCA1 mutation and 20 families with a BRCA2 mutation indicated that the carriers of each recurrent mutation have common ancestors. The common ancestors were estimated to trace back to 7-36 generations (150-800 years). The time estimates and the geographical clustering of these founder mutations in Finland are in concordance with the population history of this country. Analysis of the cancer phenotypes showed differential ovarian cancer expression in families carrying mutations in the 5' and 3' ends of the BRCA1 gene, and earlier age of ovarian cancer onset in families with BRCA1 mutations compared with families with BRCA2 mutations. The identification of prominent and regional BRCA1 and BRCA2 founder mutations in Finland will have significant impact on diagnostics in Finnish breast and ovarian cancer families. An isolated population with known history and multiple local founder effects in multigenic disease may offer distinct advantages also for mapping novel predisposing genes.
Similar articles
- Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families.
Hartikainen JM, Kataja V, Pirskanen M, Arffman A, Ristonmaa U, Vahteristo P, Ryynänen M, Heinonen S, Kosma VM, Mannermaa A. Hartikainen JM, et al. Clin Genet. 2007 Oct;72(4):311-20. doi: 10.1111/j.1399-0004.2007.00866.x. Clin Genet. 2007. PMID: 17850627 - BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients.
Sarantaus L, Vahteristo P, Bloom E, Tamminen A, Unkila-Kallio L, Butzow R, Nevanlinna H. Sarantaus L, et al. Eur J Hum Genet. 2001 Jun;9(6):424-30. doi: 10.1038/sj.ejhg.5200652. Eur J Hum Genet. 2001. PMID: 11436123 - Involvement of BRCA1 and BRCA2 in breast cancer in a western Finnish sub-population.
Pääkkönen K, Sauramo S, Sarantaus L, Vahteristo P, Hartikainen A, Vehmanen P, Ignatius J, Ollikainen V, Kääriäinen H, Vauramo E, Nevanlinna H, Krahe R, Holli K, Kere J. Pääkkönen K, et al. Genet Epidemiol. 2001 Feb;20(2):239-46. doi: 10.1002/1098-2272(200102)20:2<239::AID-GEPI6>3.0.CO;2-Y. Genet Epidemiol. 2001. PMID: 11180449 - Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
Casey MJ, Bewtra C, Hoehne LL, Tatpati AD, Lynch HT, Watson P. Casey MJ, et al. Gynecol Oncol. 2000 Sep;78(3 Pt 1):278-87. doi: 10.1006/gyno.2000.5861. Gynecol Oncol. 2000. PMID: 10985881 Review. - Hereditary breast cancer: a review.
Arver B, Du Q, Chen J, Luo L, Lindblom A. Arver B, et al. Semin Cancer Biol. 2000 Aug;10(4):271-88. doi: 10.1006/scbi.2000.0325. Semin Cancer Biol. 2000. PMID: 10966850 Review.
Cited by
- Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control.
Janavičius R. Janavičius R. EPMA J. 2010 Sep;1(3):397-412. doi: 10.1007/s13167-010-0037-y. Epub 2010 Jun 27. EPMA J. 2010. PMID: 23199084 Free PMC article. - A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancer.
Pelttari LM, Kiiski J, Nurminen R, Kallioniemi A, Schleutker J, Gylfe A, Aaltonen LA, Leminen A, Heikkilä P, Blomqvist C, Bützow R, Aittomäki K, Nevanlinna H. Pelttari LM, et al. J Med Genet. 2012 Jul;49(7):429-32. doi: 10.1136/jmedgenet-2012-100852. Epub 2012 May 31. J Med Genet. 2012. PMID: 22652533 Free PMC article. - Genetic, clinic and histopathologic characterization of BRCA-associated hereditary breast and ovarian cancer in southwestern Finland.
Pallonen TA, Lempiäinen SMM, Joutsiniemi TK, Aaltonen RI, Pohjola PE, Kankuri-Tammilehto MK. Pallonen TA, et al. Sci Rep. 2022 Apr 25;12(1):6704. doi: 10.1038/s41598-022-10519-y. Sci Rep. 2022. PMID: 35469032 Free PMC article. - Imprecise Medicine: BRCA2 Variants of Uncertain Significance (VUS), the Challenges and Benefits to Integrate a Functional Assay Workflow with Clinical Decision Rules.
Jimenez-Sainz J, Jensen RB. Jimenez-Sainz J, et al. Genes (Basel). 2021 May 20;12(5):780. doi: 10.3390/genes12050780. Genes (Basel). 2021. PMID: 34065235 Free PMC article. Review. - Commonalities in Development of Pure Breeds and Population Isolates Revealed in the Genome of the Sardinian Fonni's Dog.
Dreger DL, Davis BW, Cocco R, Sechi S, Di Cerbo A, Parker HG, Polli M, Marelli SP, Crepaldi P, Ostrander EA. Dreger DL, et al. Genetics. 2016 Oct;204(2):737-755. doi: 10.1534/genetics.116.192427. Epub 2016 Aug 12. Genetics. 2016. PMID: 27519604 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous